New Four-Year Data Demonstrate Rezūm™ Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms

Boston Scientific Corporation (NYSE: BSX) today announced that data from a randomized clinical trial demonstrate that Rezūm Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment. The study, published online ahead of print by Urology, found that patients continued to experience significant and sustained improvement in their symptoms and quality of life over this period.